Xbrane down 12% today - big buying opportunity
Xbrane is down on termination of Bauch and Lomb partnership.
The share went down to SEK60, now recovered to SEK67.
Just the European business is worth double of the current share price.
The CEO on the call today said he was confident, that Xbrane would find equally strong US partner with better terms than Bauch and Lomb, as the contract with them was signed in 2020 before the Xlucane approvals and commercionalization.
The share went down to SEK60, now recovered to SEK67.
Just the European business is worth double of the current share price.
The CEO on the call today said he was confident, that Xbrane would find equally strong US partner with better terms than Bauch and Lomb, as the contract with them was signed in 2020 before the Xlucane approvals and commercionalization.
NordicGuy
25.07.2023 kl 13:44
1206
Good summary of the call with the CEO today
https://fitinvestmentideas.com/2023/07/25/xbrane-down-20-today-why-we-bought/
https://fitinvestmentideas.com/2023/07/25/xbrane-down-20-today-why-we-bought/
NordicGuy
29.02.2024 kl 16:23
1044
NordicGuy
06.03.2024 kl 08:56
1002
I found Xbrane one of the most interesting opportunities in Sweden now
Redeye report from today:
https://www.redeye.se/research/988345/xbrane-biopharma-additional-subscription-commitments?utm_source=MB&utm_medium=email
Redeye report from today:
https://www.redeye.se/research/988345/xbrane-biopharma-additional-subscription-commitments?utm_source=MB&utm_medium=email
NordicGuy
17.05.2024 kl 09:29
868
The latest report by Redeye on Xbrane titled: Q1 2024: Approaching an eventful second half of the year
download for free:
https://www.redeye.se/api/articles/download-file/63488e8b-b81f-3c3e-b02b-5fc6ef337950
download for free:
https://www.redeye.se/api/articles/download-file/63488e8b-b81f-3c3e-b02b-5fc6ef337950
NordicGuy
17.05.2024 kl 10:33
849
Redeye Investment Case for Xbrane:
Catalysts to turn the tide
Xbrane has had a turbulent first year on market with lead candidate Ximluci encountering lowerthan-anticipated sales. However, the company anticipates increasing sales and stands before several potential catalysts throughout 2024, aiming to achieve cash flow positivety by Q1 2025. The share price has plummeted following a rights issue and worry about the financing situation. Consequently, the valuation is not indicative of a clinically proven company with a promising
pipeline and low-to-no expectations are baked in for lead project Ximluci. If these catalysts materialize, we judge that the share price would climb towards our base case.
Several share price supporting catalysts ahead
The company is poised for an eventful 2024, during which high-impact catalysts across all
projects could reignite optimism. Firstly, following the resubmission of its BLA to the FDA in
mid-2023, Xbrane's lead candidate, Ximluci, could potentially gain approval in the US in the
coming 6-9 months (we estimate). Additionally, Xbrane recently outlicensed the US commercial
rights in a USD45m deal with royaltiues. Furthermore, the company’s Cimzia biosimilar, BIIB801,
is currently in the scale-up phase and production of clinical material. This material will be sold
to its partner, Biogen. Once the scale-up process is complete, Biogen will assume responsibility
for clinical development, generating a milestone. Lastly, the company has disclosed that it is in
late-stage discussions with interested parties for its third-in-line biosimilar, Xdivane. We believe
this could lead to an upfront payment in the USD7-10m range in the near to medium term
Catalysts to turn the tide
Xbrane has had a turbulent first year on market with lead candidate Ximluci encountering lowerthan-anticipated sales. However, the company anticipates increasing sales and stands before several potential catalysts throughout 2024, aiming to achieve cash flow positivety by Q1 2025. The share price has plummeted following a rights issue and worry about the financing situation. Consequently, the valuation is not indicative of a clinically proven company with a promising
pipeline and low-to-no expectations are baked in for lead project Ximluci. If these catalysts materialize, we judge that the share price would climb towards our base case.
Several share price supporting catalysts ahead
The company is poised for an eventful 2024, during which high-impact catalysts across all
projects could reignite optimism. Firstly, following the resubmission of its BLA to the FDA in
mid-2023, Xbrane's lead candidate, Ximluci, could potentially gain approval in the US in the
coming 6-9 months (we estimate). Additionally, Xbrane recently outlicensed the US commercial
rights in a USD45m deal with royaltiues. Furthermore, the company’s Cimzia biosimilar, BIIB801,
is currently in the scale-up phase and production of clinical material. This material will be sold
to its partner, Biogen. Once the scale-up process is complete, Biogen will assume responsibility
for clinical development, generating a milestone. Lastly, the company has disclosed that it is in
late-stage discussions with interested parties for its third-in-line biosimilar, Xdivane. We believe
this could lead to an upfront payment in the USD7-10m range in the near to medium term
NordicGuy
16.09.2024 kl 15:40
560
Redeye interview with Xbrane CEO
Very good update
https://www.redeye.se/research/1039525/xbrane-biopharma-interview-with-ceo-martin-amark-2?utm_source=interview&utm_medium=email
Very good update
https://www.redeye.se/research/1039525/xbrane-biopharma-interview-with-ceo-martin-amark-2?utm_source=interview&utm_medium=email